20/04/2014 00:38:02 Cookie Policy Free Membership Login


Antisoma Share Forum

Share On Facebook
Creator ecomkid Created 27 Oct 2003 Posts 1058 Last Post 9 years ago
Antisoma's R1549, formerly Pemtumomab, fails late stage ovarian cancer trials


Antisoma is a biotechnology company specialising in the development of novel anti-cancer drugs. Antisoma has a diverse portfolio of products in development, three of which are being evaluated in clinical trials. Others are undergoing the preclinical development required before clinical testing. Antisoma's product candidates target tumours by several different mechanisms and are intended for the treatment of a range of cancers. Investors Chronicle - 03/2004 

RI549 90Y-muHMFG1 OVARIAN         
RI549 90Y-muHMFG1 GASTRIC        
AS1404 SOLID TUMOURS        
R1550 BREAST        


08/12/2003 : Antisoma reports positive results from tests on mice with cancer drug-AS1406
25/11/2003 : Antisoma raises 15.2 mln stg in surprise fundraising move
Outlook for the next 12 months The company looks forward to completing the phase III trial of R1549 by early next year. Antisoma and Roche will take the preparatory steps necessary to ensure that they are well placed to exploit a positive result. They also expect to receive further results from thier pilot phase II study of R1549 in gastric cancer. While R1549 is clearly of great importance to the near-term future of the Company, they have worked continually to build a broad-based pipeline. They now have a substantial pipeline of products in development. In the coming year they intend to advance a further product, AS1405 (formerly AngioMab), into clinical trials. They expect to see the results from the ongoing trial of AS1404 and will continue, with Roche, the development of the programme to maximise the potential of R1550
Major Shareholders   Highlights - A year of transformation
  Number Percentage  
Leventis Holding SA 28,293,378 12. 41% Ground-breaking alliance formed with Roche • Injection of £27.3 million cash and reduced cash burn • Potential for future milestone and royalty payments • Clear route to market established for products Existing pipeline advanced • Lead product R1549 close to completing pivotal efficacy study • Broad development of R1550 begun with breast cancer study Pipeline strengthened by new addition • Licensing of telomerase inhibitor programme from Cancer Research Technology Ltd (in September 2003)

Roche Finance Limited 20,730,000 9.09%
GNI Limited* 12,010,400 5.27%
Merrill Lynch Investment Management* 9,924,985 4.35%
Gartmore Investment Management plc* 6,832,116 3.00%
Click here to download the Annual Report and Accounts for the financial year ended 30 June 2003 (PDF Format). Last Updated 22/03/2004  

No news found

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 140420 00:38